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One possible contributor to the reported rise in the ratio of adenocarcinoma to squamous cell carcinoma
of the lung may be differences in the pattern of decline in risk following quitting for the two lung cancer
types. Earlier, using data from 85 studies comparing overall lung cancer risks in current smokers, quitters
(by time quit) and never smokers, we ﬁtted the negative exponential model, deriving an estimate of
9.93 years for the half-life – the time when the excess risk for quitters compared to never smokers
becomes half that for continuing smokers. Here we applied the same techniques to data from 16 studies
providing RRs speciﬁc for lung cancer type. From the 13 studies where the half-life was estimable for each
type, we derived estimates of 11.68 (95% CI 10.22–13.34) for squamous cell carcinoma and 14.45 (11.92–
17.52) for adenocarcinoma. The ratio of the half-lives was estimated as 1.32 (95% CI 1.20–1.46, p < 0.001).
The slower decline in quitters for adenocarcinoma, evident in subgroups by sex, age and other factors,
may be one of the factors contributing to the reported rise in the ratio of adenocarcinoma to squamous
cell carcinoma. Others include changes in the diagnosis and classiﬁcation of lung cancer.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction to the fact that in the USA and many other countries many smo-The US Surgeon General (2014) claimed that the risk of develop-
ing lung adenocarcinoma from smoking has increased since the
1960s, and concluded that this was because of changes in the
design and composition of cigarettes since the 1950s. As support
for their claims, they argued that though a big shift from squamous
cell carcinoma (SqC) to adenocarcinoma (AdC) occurred in smo-
kers, there had been no overall change in risk of all lung cancer
or of adenocarcinoma in never smokers. They also argued that
the shift is not explained by changes in diagnostic accuracy or in
the intensity or duration of smoking. Though the discussion of this
paper does include some comment on these claims, it is not the
intention here to examine them here in full. Rather, attention is
restricted to one possible contributor to a shift in the relative dis-
tribution of the main histological types of lung cancer. This relateskers, particularly men, have quit, so that, over time, the proportion
of long-term quitters has increased. A difference in the pattern of
decline in risk following quitting for SqC and AdC might therefore
help to explain a change over time in the relative distribution of
these two lung cancer types. The main objective of this paper,
therefore, is to investigate this possibility.
In an earlier paper (Fry et al., 2013), using a database of
epidemiological studies of at least 100 cases of lung cancer, and
106 blocks of relative risks (RRs) from 85 studies comparing cur-
rent smokers, former smokers (by time quit) and never smokers,
we estimated the half-life (H, time in years where the excess risk
becomes half that for a continuing smoker) for each block by ﬁtting
the negative exponential model. In that paper, which concerned
overall lung cancer risk regardless of type, we investigated model
ﬁt, studied heterogeneity in H, and conducted sensitivity analyses
allowing for reverse causation, either by ignoring short-term quit-
ters (S1) or considering them smokers (S2). Model ﬁt was found to
be poor ignoring reverse causation, but much improved for both
sensitivity analyses. Overall estimates of H were similar for the
main and sensitivity analyses, being estimated as 9.93 (95% CI
9.31–10.60) for the best-ﬁtting sensitivity analysis (S1), though
varying by sex (females 7.92, males 10.71), and age (<50 years
6.98, 70+ years 12.99).
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compare estimates of H based on the more limited data that are
available separately for SqC and AdC.
2. Methods
2.1. Study identiﬁcation, data selection and blocks
The available data were taken from the IESLC database,
described fully earlier (Lee et al., 2012a), and the additional litera-
ture searching used for the paper on lung cancer and quitting (Fry
et al., 2013). The results considered concerned blocks of RRs for
SqC, or exceptionally for Kreyberg type I (KI) lung cancer, and for
AdC (or KII), each block consisting of RR and 95% conﬁdence inter-
val (CI) estimates, expressed relative to never smokers, for former
smokers (by time quit) and for current smokers. On occasion, RRs
were provided relative to current smokers. Where possible, blocks
were sex-speciﬁc, with RRs adjusted for covariates being preferred
to unadjusted estimates. For each block, the additional data
recorded included study type, sex, location, year of publication,
age range, deﬁnition of product smoked, and deﬁnition of never
smoker, as described earlier (Fry et al., 2013). For each RR in each
block, the range of each quitting period was also recorded.
2.2. Analysis
As before, the ﬁrst analysis step was to use the method of
Hamling et al. (2008) in each block, to estimate the pseudo-table
of numbers of cases and of controls/at risk corresponding to the
observed RRs and 95% CIs. Blocks involving less than 10 cases in
quitters were omitted. Midpoint estimates for quitting periods
were derived as described by Lee et al. (2012b). That paper also
describes the maximum likelihood methods used to estimate H
(in years) and its SE.
For prospective studies, the underlying model ﬁtted to a block
was:
Pj ¼ Aþ Bexp ðCtjÞ
where Pj is the absolute risk of lung cancer for time quit tj in group j
and A, B and C are parameters to be estimated. Here A is the risk in
never smokers (tj = inﬁnite) and B is the excess absolute risk in
current smokers (tj = 0), i.e. the increase in absolute risk compared
to never smokers. The term exp (Ctj) models the proportional
decline in excess absolute risk for quitters, declining asymptotically
from 1 to 0, as time increases. H is estimated by:
0:5 ¼ expðCHÞ
or
H ¼ ðloge2Þ=C
For case-control studies, the model used was:
Fj ¼ 1þ Bexp ðCtjÞ
where Fj is the RR (compared to never smokers) rather than the
absolute risk and H is estimated as before. While C, and thus H, have
the same interpretation as for prospective studies, the inter-
pretation of B is different, being the excess relative risk (relative risk
in current smokers minus 1) rather than the excess absolute risk.
For both prospective and case-control studies the method,
described fully elsewhere (Lee et al., 2012b), allows estimation of
the ﬁtted RRs and numbers of cases and controls/at risk by level
corresponding to the observed RRs and (pseudo-) numbers, and
testing for goodness-of-ﬁt by an approximate chisquared statistic.
Sensitivity analyses S1 and S2 were conducted as brieﬂy
described above. In S1 RRs for quitters relating to the shortest quittime were omitted from each block, while in S2 all RRs for quitters
in each block relating to a range of quit times with upper limit at
most three years were considered to be current smokers.
Overall estimates ofH (with 95% CI) were derived, and sources of
heterogeneity studied using inverse-variance weighted regression
of log H,with estimates converted back to the original scale. The fac-
tors studied were sex, study type, location (continent), publication
year, midpoint age of subjects (at baseline for prospective studies)
and current smoker RR. Sources of heterogeneity were ﬁrst studied
based on an analysis which included all the available estimates for
each lung cancer type. A second analysis was restricted to matched
estimates, only using data from blocks which provided valid esti-
mates of H for both lung cancer types, so as to avoid confounding
by aspects of study quality and conduct. A ﬁnal analysis, restricted
to the matched estimates, was based on inverse-variance weighted
regression of the logarithm of the ratio (H for AdC)/(H for SqC).3. Results
3.1. Studies providing data
Table 1 summarizes some details of the 16 studies and 19 blocks.
Three studies provided sex-speciﬁc data, one data for the sexes com-
bined, and the rest data for a speciﬁc sex (nine males and three
females). Six of the studies were conducted in Europe, four in
NorthAmerica, three in SouthAmerica, and three in Asia. Apart from
two prospective studies, both in the USA, all the other studies were
of case-control design. The earliest study (WYNDE3)was conducted
in 1966–1968, with the latest (TSE) in 2004–2006. Most studies
started in the 1980s or 1990s. Three studies (IARC, LEITZM,
LUBIN2) were clearly larger than the rest, involving about 7000
cases. A further ﬁve studies (JEDRYC, KUBIK2, PARK, SPEIZE, TSE)
included over 1000 cases, with no study less than 200 cases. Of the
16 studies, 13 provided separate information for SqC and AdC, two
information for AdC only, and one, the earliest, for KI and KII.
3.2. The data blocks
Tables 2 (SqC) and 3 (AdC) give the RRs for each block. Data are
shown ﬁrst for the group considered current smokers in analysis
(withmean quit time 0) and then for the former smokers by increas-
ing timeof quit. In a number of the blocks, as indicated in the column
‘‘time quit groupings’’, current smokers are combined with recent
quitters, the longest such combination being up to 5 years in
JEDRYC and WAKAI. In 14 of the 17 blocks for SqC and 13 of the 19
blocks for AdC, the RRs for quitters (ignoring current smokers)
decrease strictly monotonically with increasing time quit, and in
all the remaining blocks except one (PARK, AdC) the RR for the long-
est quit time is less than that for the shortest. Current smoker RRs for
SqC are alwayshigher than those for AdC in the corresponding block,
with the exception of MATOS, where they are equal. However, for
both histological types, there is considerable variation in the current
smokingRRs, from4.17 (PARK) to 101.66 (PEZZOT) for SqC, and from
0.87 (PARK) to 13.01 (KUBIK2) for AdC. For SqC, the RR for the short-
est quitting time is usually less than that for current smokers, but
there are four blocks (KUBIK2, females, LUBIN2 males, LUBIN2
females, TSE) where it is greater, and one (PARK) where it is equal.
For AdC, there are ﬁve blocks (BARBON, DESTE5, KUBIK2 females,
LUBIN2 males, MATOS) where the RR for the shortest quitting time
is greater than that for current smokers.
3.3. Fit to the negative exponential model and half-life estimates
Table 4 compares the observed number of cases of SqC and of
AdC, summed over blocks for never smokers, for current smokers
Table 1
Study and block details.
Block: Studya Sexb Location Study typec Yearsd Total lung cancer cases Data available by typee
1: BARBON M Italy CC 1979–1986 755 SqC, AdC
2: DESTE5 M Uruguay CC 1994–2000 338 AdC
3: IARC F Europe CC 1988–1994 7609 SqC, AdC
4: JAIN M Canada CC 1981–1985 403 SqC, AdC
5: JAIN F Canada CC 1981–1985 442 SqC, AdC
6: JEDRYC M Poland CC 1990–1987 1630 SqC, AdC
7: KUBIK2 M Czech Republic CC 1998–2006 509 SqC, AdC
8: KUBIK2 F Czech Republic CC 1998–2006 587 SqC, AdC
9: LEITZM M + F USA P 1995–1996, 2003 6745 SqC, AdC
10: LUBIN2 M West Europe CC 1976–1980 6920 SqC, AdC
11: LUBIN2 F West Europe CC 1976–1980 884 SqC, AdC
12: MATOS M Argentina CC 1994–1996 200 SqC, AdC
13: PARK M Korea CC 1997–1998 1538 SqC, AdC
14: PEZZOT M Argentina CC 1987–1991 215 SqC, AdC
15: SPEIZE F USA P 1976–1976, 2004 1237 SqC, AdC
16: SVENSS F Sweden CC 1983–1986 210 AdC
17: TSE M China (Hong Kong) CC 2004–2006 1208 SqC, AdC
18: WAKAI M Japan CC 1988–1991 333 SqC, AdC
19: WYNDE3 M USA CC 1966–1968 350 KI, KII
a Studies are identiﬁed by a six digit character code. Corresponding references are BARBON (Barbone et al., 1997), DESTE5 (de Stefani et al., 2005), IARC (Agudo et al., 2000),
JAIN (Risch et al., 1993), JEDRYC (Jedrychowski et al., 1992), KUBIK2 (Kubik et al., 2008), LEITZM (Leitzmann et al., 2009), LUBIN2 (Lubin and Blot, 1984), MATOS (Matos et al.,
1998), PARK (Park et al., 2010), PEZZOT (Pezzotto et al., 1993), SPEIZE (Kenﬁeld et al., 2008), SVENSS (Svensson et al., 1989), TSE (Tse et al., 2011), WAKAI (Wakai et al., 1997),
and WYNDE3 (Wynder et al., 1970). Blocks involving less than 10 quitters were not considered for females for study PARK (SqC and AdC), for SqC for study SVENSS, and for
study LEE (squamous and small cell carcinomas, and AdC) (Lee et al., 2001). Data for females for study WYNDE3, and also studies BROWN3 (Alavanja et al., 1992), LUO (Luo
et al., 1996), SOBUE (Sobue et al., 1991) and WYNDE6 (Wynder and Stellman, 1977), were not considered as data were not available for complete blocks, and for studies
ALDERS (Lee, 1983) and HAMMON (Hammond and Horn, 1958) as conﬁdence intervals were not available.
b M = male, F = female.
c CC = case-control, P = prospective.
d For prospective studies the range of the baseline period is followed by the ﬁnal year of follow-up.
e KI = Kreyberg I, KII = Kreyberg II.
Table 2
Relative risks (vs. never smokers) of squamous cell carcinoma for current smokers and quitters by time of quit for each block.
Block: Study Sex Time quit groupingsa Mean values Relative risks Mb
1: BARBON M 0, <5, 5, 15, 25+ 0, 3, 10, 20, 38 19.30, 18.70, 11.90, 8.10, 1.90 M
3: IARC F <2, 2, 10, 20+ 0, 6, 15, 35 12.89, 7.23, 4.15, 1.06 M
4: JAIN M <2, 2, 10+ 0, 6, 30.5 38.54, 22.17, 8.65 M
5: JAIN F <2, 2, 10+ 0, 6, 30.5 29.18, 14.86, 4.09 M
6: JEDRYC M <5, 5, 10+ 0, 7.5, 30.5 21.94, 12.92, 4.82 M
7: KUBIK2 M 60.5, >0.5, 10, 20+ 0, 5.25, 15,35 87.71, 74.96, 20.01, 9.42 M
8: KUBIK2 F 60.5, >0.5, 10, 20+ 0, 5.25, 15, 35 10.94, 11.44, 3.70, 1.13 M
9: LEITZM C <1, 1, 10+ 0, 5.5, 30 79.78, 52.37, 14.76 M
10: LUBIN2 M 0, <5, 5, 10, 15, 20+ 0, 3, 7.5, 12.5, 17.5, 35.5 19.66, 23.04, 14.56, 10.21, 6.79, 4.55 M
11: LUBIN2 F 0, <10, 10, 20+ 0, 5.5, 15, 35.5 6.16, 6.56, 2.48, 1.13 M
12: MATOS M <1, 1, 6, 11+ 0, 3.5, 8.5, 31 10.00, 7.00, 6.00, 2.00 M
13: PARK M <0.083c, 0.083, 3+ 0, 1.54, 26.5 4.17, 4.17, 1.92
14: PEZZOT M <1, 1, 11+ 0, 6, 31 101.66, 60.72, 18.60 M
15: SPEIZE F 0, 62, >2 0, 1, 18.5 33.30, 7.00, 2.33 M
17: TSE M <1, 1, 2, 3, 4, 5, 10, 15, 20+ 0, 1.5, 2.5, 3.5, 4.5, 7. 5, 12.5, 17.5, 35 50.00, 85.50, 17.00, 31.00, 11.00, 11.00, 10.00, 8.00,
7.50
18: WAKAI M <5, 5, 10, 20+ 0, 7.5, 15, 35.5 10.15, 7.47, 8.95, 2.05
19: WYNDE3 M <1, 1, 4, 7, 13+ 0, 2.5, 5.5, 10, 32 24.23, 24.00, 13.80, 7.57, 1.07 M
a The ﬁrst group is considered as current smokers in analysis. Entries other than 0 for the ﬁrst group imply that short-term quitters were included among the current
smokers. <n implies less than n if no previous 0, and less than n but greater than 0 otherwise (and similarly 6n for less than or equal to n). n-implies greater than or equal to n
but less than the next number cited. >n-implies greater than (but not equal) to n and less than the next number cited. n+ implies greater than or equal to n.
b M indicates a strictly monotonic decline in RR with increasing time quit. This ignores the ﬁrst RR, which is for current smokers.
c 0.083 represents 1 month (study PARK).
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bers for each of the three analyses for each of the three analyses
(main, S1, S2). For SqC there is some evidence of misﬁt (p < 0.05)
in the main analysis, mainly due to underestimating the number
of cases in short-term quitters, particularly quitting from 2 to less
than 5 years. The same is true for AdC, though here evidence of
misﬁt is seen more clearly for quitting of up to 2 years, and the sig-
niﬁcance of the overall ﬁt is less marked (0.05 < p < 0.1). The ﬁt is
excellent for sensitivity analysis S1, for both SqC and AdC and also
for AdC for S2. The ﬁt for S2 is no better than that for the main
analysis for S2.Table 5 gives, for each block, ﬁtted values of H (in years) for the
main and the two sensitivity analyses, and the pseudo-numbers of
cases in quitters. For SqC the numbers of cases in LUBIN2 males
(1082) and LEITZM (663) are much larger than in any of the other
blocks (maximum 95), while for AdC LEITZM (1497) has the largest
number, with only LUBIN2 males (213), TSE (128.3) and DESTE5
(111) having more than 100 cases. For SqC, the main negative
exponential model ﬁtted the data adequately (pP 0.1) in all but
three blocks. The principal exception (p < 0.001) was the large
LUBIN2 males block, where the misﬁt was due to the increased
RR in short-term quitters. Other exceptions (p < 0.05) were
Table 3
Relative risks (vs. never smokers) of adenocarcinoma for current smokers and quitters by time of quit for each block.
Block: Studya Sex Time quit groupings Mean values Relative risks Mb
1: BARBON M 0, <5, 5, 15, 25+ 0, 3, 10, 20, 38 8.20, 9.40, 7.30, 4.60, 1.80 M
2: DESTE5 M 0, <10, 10, 20+ 0, 5, 15, 35 5.99, 6.65, 1.74, 3.04
3: IARC F <2, 2, 10, 20+ 0, 6, 15, 35 4.09, 1.90, 0.79, 0.54 M
4: JAIN M <2, 2, 10+ 0, 6, 30.5 10.81, 7.39, 2.63 M
5: JAIN F <2, 2, 10+ 0, 6, 30.5 6.21, 3.46, 0.44 M
6: JEDRYC M <5, 5, 10+ 0, 7.5, 30.5 5.44, 4.53, 2.15 M
7: KUBIK2 M 60.5, >0.5, 10, 20+ 0, 5.25, 15, 35 13.01, 6.61, 6.23, 3.56 M
8: KUBIK2 F 60.5, >0.5, 10, 20+ 0, 5.25, 15, 35 4.03, 4.90, 2.07, 1.79 M
9: LEITZM M+F <1, 1, 10+ 0, 5.5, 30 12.41, 8.79, 4.14 M
10: LUBIN2 M 0, <5, 5, 10, 15, 20+ 0, 3, 7.5, 12.5, 17.5, 35.5 3.36, 3.38, 2.60, 1.99, 2.02, 1.42
11: LUBIN2 F 0, <10, 10, 20+ 0, 5.5, 15, 35.5 1.44, 1.17, 0.78, 0.29 M
12: MATOS M <1, 1, 6, 11+ 0, 3.5, 8.5, 31 10.00, 13.00, 10.00, 3.00 M
13: PARK M <0.083c, 0.083, 3+ 0, 1.54, 26.5 0.87, 0.45, 0.99
14: PEZZOT M <1, 1, 11+ 0, 6, 31 12.59, 5.19, 2.55 M
15: SPEIZE F <0.1, 2,>2 0, 1, 18.5 7.14, 2.00, 1.93 M
16: SVENSS F 62, >2, 11+ 0, 7, 31 3.91, 2.10, 1.59 M
17: TSE M <1, 1, 2, 3, 4, 5, 10, 15, 20+ 0, 1.5, 2.5, 3.5, 4.5, 7.5, 12.5, 17.5, 35 7.69, 6.62, 4.31, 3.69, 4.38, 1.85, 1.69, 2.23, 2.00
18: WAKAI M <5, 5, 10, 20+ 0, 7.5, 15, 35.5 2.15, 1.23, 2.49, 0.54
19: WYNDE3 M <1, 1, 4, 7, 13+ 0, 2.5, 5.5, 10, 32 3.97, 2.00, 2.59, 1.42, 0.80
a The ﬁrst group is considered as current smokers in analysis. Entries other than 0 for the ﬁrst group imply that short-term quitters were included among the current
smokers. <n implies less than n if no previous 0, and less than n but greater than 0 otherwise (and similarly 6n for less than or equal to n). n-implies greater than or equal to n
but less than the next number cited. >n-implies greater than (but not equal) to n and less than the next number cited. n+ implies greater than or equal to n.
b M indicates a strictly monotonic decline in RR with increasing time quit. This ignores the ﬁrst RR, which is for current smokers.
c 0.083 represents 1 month (study PARK).
Table 4
Observed and ﬁtted cases for the main analyses and the two sensitivity analyses with H ﬁtted separately for each block.
Time of quitting smoking Main analysis Sensitivity S1a Sensitivity S2b
Observedc Fittedd Observedc Fittedd Observedc Fittedd
Squamous cell carcinoma
Current smokers 5377.25 5419.57 5377.25 5368.43 5390.05 5438.32
<2 61.82 66.19 – – 49.02 47.97
2 to <5 546.70 464.39 16.24 21.71 546.70 464.10
5 to <10 907.92 922.39 288.38 280.26 907.92 921.84
10 to <15 193.71 204.85 193.71 199.44 193.71 204.44
15 to <20 80.81 96.50 80.81 94.81 80.81 97.26
20+ 582.67 567.72 582.67 569.65 582.67 67.79
Never smokers 303.63 307.28 303.63 307.53 303.63 307.17
Total 8127.76 8127.79 6915.93 6915.83 8127.76 8127.78
Fit statistice 26.19 5.43 27.94
p <0.05 NS <0.05
Adenocarcinoma
Current smokers 3347.62 3299.28 3455.91 3457.84 3365.06 3335.91
<2 17.44 37.90 – – – –
2 to <5 127.57 118.33 30.02 30.03 127.57 118.19
5 to <10 901.38 840.95 76.27 76.70 901.38 940.87
10 to <15 71.66 71.41 71.66 70.93 71.66 71.38
15 to <20 105.05 97.04 105.05 98.75 105.05 99.11
20+ 1127.57 1108.83 1150.56 1142.40 1127.57 1108.84
Never smokers 921.35 927.33 970.17 980.29 921.35 926.75
Total 6691.69 6691.75 5931.68 5931.68 6691.69 6691.74
Fit statistice 15.50 0.69 3.67
p P0.1 NS NS
a Omitting the estimate in each block with the shortest quitting period.
b Counting estimates with an upper limit of quitting time of up to 3 years as applying to current smokers.
c Observed pseudo-number of lung cancer cases, summed over block.
d Fitted pseudo-number of lung cancer cases, summed over blocks. For each study, the ﬁtted number of cases for each block is calculated from the numbers at risk and the
ﬁtted relative risks by time quit, derived from the ﬁtted value of H.
e Based on summation of (observed  ﬁtted)2/ﬁtted, the summation also including terms for the observed and ﬁtted total number of controls (not shown). The statistic can
be considered to be approximately chi squared distributed on 12 df.
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smokers to 7.00 in quitters of less than 2 years, and TSE, where
there was an increase in short-term quitters and non-monotonicity
subsequently. For AdC, a ﬁt could not be derived for PARK, where
there was no evidence of any increased risk in current smokers
or ex-smokers. There were also three cases where there was sig-
niﬁcant misﬁt (p < 0.1) to the model). The most marked misﬁt(p < 0.001) was for SPEIZE where the RR again dropped massively,
on short-term quitting with no evidence of any subsequent
decline. Other cases were DESTE5 (p < 0.05), where there was an
increase in short-term quitters and non-monotonicity subse-
quently, and LEITZM (0.05 < p < 0.1), where the decline after an
estimated average 5.5 years quitting was somewhat more than
expected given the decline after 3 years quitting. In sensitivity
Table 5
Estimated half-life (H) in years and number of cases in quitters for the main and sensitivity analyses.a
Block: Study SqC
casesb
SqC H(main) SqC H(S1) SqC H(S2) AdC
cases
AdC (main) AdC H(S1) AdC H(S2)
1: BARBON 56.4 11.55 11.54 11.55 41.8 17.04 17.05 17.04
2: DESTE5 – – – – 111.0 15.90⁄ 2.15 15.90⁄
3: IARC 78.9 6.99 7.11 6.99 60.8 3.02 10.31 3.02
4: JAIN 47.0 13.32 13.29 13.32 30.0 11.70 11.79 11.70
5: JAIN 22.0 9.19 9.57 9.19 17.0 4.54 1.07 4.54
6: JEDRYC 45.0 12.21 12.42 12.21 21.0 15.98 15.69 15.98
7: KUBIK2 95.0 9.58 9.48 9.58 39.1 15.28 15.16 15.28
8: KUBIK2 55.2 8.83 7.54 8.84 71.8 15.64 14.00 15.64
9: LEITZM 663.0 12.03 11.92 12.03 1497.0 16.49(⁄) 16.11 16.49(⁄)
10: LUBIN2 1082.0 13.80⁄⁄⁄ 13.70 13.80⁄⁄⁄ 213.0 13.37 13.05 13.37
11: LUBIN2 45.0 12.47 8.00 12.47 17.0 3.42 0.30 3.42
12: MATOS 11.8 9.72 9.82 9.72 33.3 14.68 14.75 14.68
13: PARK 79.2 14.84 14.82 14.84 31.6 – – –
14: PEZZOT 30.0c 12.19 12.32 12.19 18.0 3.89 10.69 3.89
15: SPEIZE 10.0 3.63⁄ 4.02 4.13 76.6 6.70⁄⁄⁄ 6.79 7.00
16: SVENSS – – – – 12.0 11.40 13.48 11.40
17: TSE 61.3 4.54⁄ 4.75(⁄) 4.29 128.3 2.97 2.95 2.97
18: WAKAI 26.2 17.21 17.48 17.21 23.0 13.23 15.63 13.23
19: WYNDE3 36.0 5.60 5.40 5.60 12.0 3.75 4.37 3.75
Meand (95%
CI)
11.64 (10.42–
13.00)
11.47 (10.17–
12.93)
11.52 (10.20–
13.02)
14.01 (11.32–
17.33)
14.44 (12.34–
16.89)
14.00 (11.32–
17.29)
a Probability values are coded as follows ⁄⁄⁄ = p < 0.001, ⁄⁄ = p < 0.01, ⁄ = p < 0.05, (*) = p < 0.1.
b Pseudo-numbers of cases in quitters. Where numbers and not RRs were provided in the source document, these are actual numbers.
c The actual number was 29, but as there were no never smokers, the estimation was carried out by adding 0.5 to each cell of the numbers of cases (and controls).
d The inverse-variance weighted mean of log H, converted back to the original scale.
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ﬁt signiﬁcant at p < 0.05. Though estimates of H for speciﬁc studies
varied somewhat between S1 and the main analysis, the overall
effect was quite small. Thus, for SqC the estimate of 11.64 (95%
CI 10.42–13.00) from the main analysis reduced only slightly to
11.47 (10.17–12.93), while for AdC the main effect estimate of
14.01 (11.32–17.33) increased slightly, to 14.44 (12.34–16.89).
The effect of sensitivity analysis S2 was negligible for both SqC
and AdC, with individual study estimates never materially chang-
ing, and the combined estimates, 11.52 (10.20–13.02) for SqC
and 14.00 (11.32–17.29) for AdC very similar to those from the
main analysis.3.4. Heterogeneity analyses
Table 6 shows the results of inverse-variance weighted simple
regression analysis of log H based on analysis S1. Compared to
Table 5, results for AdC for three blocks (IARC, JAIN females, and
LUBIN2 females) were excluded from analysis as the estimates of
log H had extremely small weight. For both SqC and AdC, there
was no signiﬁcant evidence that H varied by study type, continent
or publication year. Nor was there any consistent evidence regard-
ing the dependence of H on current smoker RR, with no signiﬁcant
variation for SqC, and the signiﬁcant (p < 0.001) variation for AdC
difﬁcult to interpret, with H relatively high for low and high
current smoker RRs and relatively low for intermediate current
smoker RRs. There was, however, consistent evidence for both
SqC and AdC that H was higher for males than females (SqC
p < 0.05; AdC p < 0.01), and increased with age (SqC p < 0.05; AdC
p < 0.001).
Though the analyses in Table 6 provide the most powerful
analyses of the results for the individual lung cancer types,
comparison of results between the types may be confounded by
differences in the blocks used. The analysis in Table 7 corresponds
to Table 6, but is restricted to those 13 blocks (see footnote a to
Table 7) which provide matched estimates for the same block.
The overall estimates of H are now 11.68 (95% CI 10.22–13.34)for SqC and 14.45 (11.92–17.52) for AdC, quite similar to those in
Table 6. The pattern of estimates by the factors studied is also very
similar.
3.5. Comparison of estimates for SqC and AdC
Again, using the results from analysis S1, and using the matched
estimates from 13 studies, Table 8 presents results for the log of
the ratio (H for AdC)/(H for SqC). The ratio of H was estimated as
1.32 (95% CI 1.20–1.46, p < 0.001). There was no signiﬁcant
(p < 0.05) evidence that the ratio varied by any of the factors stud-
ied. However, there was some suggestion (p < 0.1) that estimates
were higher for females than males, and for more recently
published studies.
4. Discussion
For overall lung cancer, 106 blocks of RRs from 85 studies
provided data for estimation of H. In contrast, far fewer data were
available by lung cancer type, with 19 blocks of RRs from 16 stud-
ies. Nevertheless there were sufﬁcient results to provide reason-
able estimates of H separately for SqC and AdC. Based on all
available useful estimate for each type, H was estimated as 11.47
(95% CI 10.17–12.93) for SqC and 14.44 (12.11–17.22), based on,
respectively, 17 and 15 independent estimates. Limiting attention
to the 13 pairs of estimates with H was available for both types
from the same block (so avoiding potential confounding by differ-
ences in design and conduct between study), the estimates of H
were very similar, being 11.68 (10.22–13.34) for SqC and 14.45
(11.92–17.52) for AdC. Again based on the matched pairs, the ratio
of H for AdC to SqC was estimated as 1.32 (1.20–1.46).
As for overall lung cancer risk, the best ﬁt to the data was
obtained using a sensitivity analysis (S1), where short-term quit-
ters were ignored in the analysis. While there were some excep-
tions in individual studies, the overall ﬁt (for S1) to the negative
exponential model was very good, closely predicting the shape of
the decline with time quit. The results cited in the previous
paragraph come from this analysis.
Table 6
Time quit – inverse-variance weighted simple regression analysis of log H based on sensitivity analysis S1.
Factor Level SqC AdC
n H (95% CI)a pb nc H (95% CI)a pb
All 17 11.47 (10.17–12.93) 15 14.44 (12.11–17.22)
Sex Male 11 12.09 (10.38–14.08) <0.05 11 11.35 (8.00–16.11) <0.01
Female 5 6.73 (4.78–9.47) 3 7.34 (4.76–11.31)
Combinedd 1 11.92 (10.47–13.57) 1 16.11 (14.01–18.53)
Study type Case-control 15 11.40 (9.46–13.72) NS 13 11.50 (7.14–18.53) NS
Prospective 2 11.53 (9.75–13.63) 2 14.97 (12.39–18.08)
Continent North America 5 11.38 (9.56–13.54) NS 4 14.84 (12.40–17.75) NS
Europe 7 11.65 (9.29–14.59) 6 14.72 (7.79–27.81)
Asia 3 10.60 (3.67–30.59) 2 4.00 (1.11–14.45)
Other 2 11.81 (4.57–30.47) 3 12.90 (4.78–34.82)
Publication yeare <1991 3 12.92 (10.01–16.69) NS 3 11.53 (3.89–34.20) NS
1991–1995 4 12.12 (8.10–18.13) 3 12.12 (4.83–30.41)
1996–2000 4 8.20 (4.76–14.13) 4 8.77 (5.17–14.86)
2001–2005 1 7.11 (3.61–14.02) 1 2.15 (0.00–5.44 x 107)
2005–2011 5 11.47 (9.87–13.33) 4 15.61 (12.93–18.85)
Grouped midpoint age <50 2 5.80 (3.74–9.02) <0.05 1 6.79 (4.40–10.48) <0.01
50–59 13 11.74 (10.11–13.63) 12 11.42 (8.26–15.79)
60–69 2 11.96 (10.50–13.63) 2 16.11 (14.11–18.39)
Current smoker RR <4 0 – NS 4 11.93 (6.57–21.66) <0.001
4–7.9 2 11.86 (3.18–44.25) 5 6.72 (4.91–9.20)
8–15.9 4 8.10 (4.76–13.78) 6 15.89 (14.27–17.69)
16+ 11 11.69 (10.32–13.24) 0 –
a The inverse-variance weighted mean of log H, converted back to the original scale (in years).
b Probability values for testing for variation between levels of the factor considered, presented as <0.001, <0.01, <0.05, <0.1 or NS (pP 0.1). The probability level is
calculated based on the difference in deviance between the model with a common estimate of H and the model with a separate estimate of H ﬁtted for each level of the factor
studied.
c Results for IARC, JAIN females, and LUBIN2 females omitted from the analysis of adenocarcinoma as the estimates of H had very small weight.
d Blocks where risk was not separately estimated for males and females.
e Of principal publication for the study.
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cancer types, H values were somewhat higher for men than for
women, and increased with the age of the population studied.
However, there was no clear evidence that the ratio of H for AdC
to SqC varied by these factors, the results shown in Table 8 being
consistent with H being longer for AdC regardless of sex, age, study
type or continent. There was a suggestion of variation by pub-
lication year, with the ratio higher for more recent studies, but this
did not achieve formal signiﬁcance (0.05 < p < 0.1). However, the
relatively small number of studies limits the extent to which varia-
tion in H or the ratio of H between types can usefully be studied.
Generally, the results seem to conﬁrm the usefulness of nega-
tive exponential model for modelling the pattern of decline in risk
following quitting. Issues relating to the interpretation of the
results resulting from misclassiﬁcation of smoking status or time
quit, reverse causation, deﬁning midpoints of ranges, the use of
pseudo-numbers, and adjustment for other smoking variables are
discussed in the paper on overall lung cancer risk (Fry et al., 2013).
It should be noted that our analyses assume that the propor-
tional decline in excess risk following quitting for a given lung can-
cer type is the same for those with a high RR at baseline as it is for
those with a low RR. Thus, for example, it is assumed that the time
taken for a smoker with a RR of 21 at baseline to halve his excess
RR (of 20 to 10, so producing a RR of 11) is the same as the time
taken for a smoker with a baseline RR of 5 to halve his excess RR
of 4 to 2, so producing a RR of 3). To test this formally would
require data on the decline in risk following quitting to be
presented separately by amount smoked, duration of smoking or
pack-years, but no such data are available by histological type of
lung cancer. Some support for this assumption is given by the rela-
tively similar estimates of H for studies with a low and high current
smoker RR (see Tables 6 and 7), but clearly it would be better if we
could have tested for this within-study.As noted earlier, there has been a large shift in the observed
ratio of AdC to SqC, and it has been suggested (US Surgeon
General, 2014) that this may be due to changes in cigarette design
and composition since the 1950s. In considering this suggestion
various points have to be borne in mind.
First, there is little or no supportive evidence for this from epi-
demiological evidence of risk in relation to type of cigarette, as
shown in reviews (Lee, 2001; Lee et al., 2012a; Lee and Sanders,
2004) of studies published in the last century, and from more
recent evidence (Brooks et al., 2003, 2005; Harris et al., 2004;
Marugame et al., 2004; Muscat et al., 2005; Papadopoulos et al.,
2011; Woodward, 2001). This evidence relates to two indices, com-
parison of risk in ﬁlter and plain cigarette smokers and comparison
by tar level of the cigarette smoked. For overall lung cancer, the
evidence shows a clear reduction in risk for both indices of tar
reduction, seen in US and non-US studies and regardless of the
extent of confounder adjustment. Evidence on risk by type of lung
cancer is mainly limited to the ﬁlter/plain comparison, and shows a
very clear reduction in risk of SqC, but no clear reduction in risk of
AdC. Generally, these results indicate that the switch to lower yield
products would have led to some increase in the relative frequency
of AdC to SqC in smokers, would not have led to an increase in the
risk of AdC, and would have reduced overall lung cancer risk.
Second, extensive, recently reviewed (Scherer and Lee, 2014),
evidence from 19 brand-switching studies (9 in the USA) and 26
cross-sectional studies (11 in the USA) where a ‘‘compensation
index’’ can be estimated, clearly indicates that switching to
lower yield cigarettes decreases the effective dose to the smoker
and so seems likely to decrease the risk of lung cancer. While
compensation is substantial, it is not complete. Thus, the overall
compensation index estimate of 0.744 (95% CI 0.682 to 0.806)
reported for brand-switching studies is consistent with a 25%
decrease in yield producing a 7.1% decrease in biomarker level,
Table 7
Time quit – inverse-variance weighted simple regression analysis of log H based on sensitivity analysis S1 for the 13 matched estimates.a
Factor Level n SqC AdC
H (95% CI)b pc H (95% CI)b pc
All 13 11.68 (10.22–13.34) 14.45 (11.92–17.52)
Sex Male 10 12.06 (10.13–14.35) <0.05 11.37 (7.73–16.72) <0.05
Female 2 5.23 (2.78–9.83) 7.20 (4.43–11.68)
Combinedd 1 11.92 (10.29–13.81) 16.11 (13.81–18.80)
Study type Case-control 11 11.88 (9.56–14.77) NS 11.48 (6.74–19.56) NS
Prospective 2 11.53 (9.59–13.86) 14.97 (12.15–18.44)
Continent North America 4 11.43 (9.37–13.94) NS 14.84 (12.11–18.18) NS
Europe 5 12.24 (9.37–15.99) 14.77 (7.08–30.80)
Asia 2 8.97 (2.08–38.75) 4.00 (0.93–17.15)
Other 2 11.81 (4.05–34.40) 12.98 (4.21–40.08)
Publication yeare <1991 2 13.01 (9.64–17.56) NS 11.32 (3.31–38.69) NS
1991–1995 3 12.70 (7.60–21.22) 12.12 (4.53–32.42)
1996–2000 4 8.20 (4.35–15.45) 8.77 (4.99–15.42)
2001–2005 0 – –
2005–2011 4 11.45 (9.60–13.65) 15.61 (12.76–19.10)
Grouped midpoint age <50 1 4.02 (1.76–9.17) <0.05 6.79 (4.18–10.01) <0.01
50–59 10 11.82 (9.96–14.04) 11.40 (7.91–16.42)
60–69 2 11.96 (10.34–13.84) 16.11 (13.90–18.67)
Current smoker RR <4 0f – NS 11.78 (5.85–23.70) <0.01
4–7.9 0 – 6.72 (4.73–9.55)
8–15.9 3 9.75 (3.84–24.77) 15.89 (14.09–17.92)
16+ 10 11.72 (10.18–13.50) -
a Based on blocks 1, 4, 6–10, 12, 14, 15, 17–19 as deﬁned in Table 1.
b The inverse-variance weighted mean of log H, converted back to the original scale (in years).
c Probability values for testing for variation between levels of the factor considered, presented as <0.001, <0.01, <0.05, <0.1 or NS (pP 0.1). The probability level is
calculated based on the difference in deviance between the model with a common estimate of H and the model with a separate estimate of H ﬁtted for each level of the factor
studied.
d Blocks where risk was not separately estimated for males and females.
e Of principal publication for the study.
f Here the numbers of blocks are for SqC; those for AdC are 3, 4, 6 and 0.
Table 8
Time quit – inverse-variance weighted simple regression analysis, based on sensitiv-
ity analysis S1 for the 13 matched estimates,a of the log of the ratio of the H for AdC to
the H for SqC.
Factor Level n Ratio (95% CI)b pc
All 13 1.32 (1.20–1.46)
Sex Male 10 1.10 (0.90–1.36) <0.1
Female 2 1.72 (1.17–2.52)
Combinedd 1 1.35 (1.23–1.49)
Study type Case-control 11 1.13 (0.91–1.41) NS
Prospective 2 1.37 (1.24–1.51)
Continent North America 4 1.35 (1.22–1.49) NS
Europe 5 1.32 (0.99–1.75)
Asia 2 0.69 (0.32–1.49)
Other 2 1.06 (0.58–1.95)
Publication yeare <1991 2 0.93 (0.62–1.40) <0.1
1991–1995 3 0.96 (0.67–1.37)
1996–2000 4 1.55 (1.14–2.10)
2001–2005 0 – –
2005–2011 4 1.35 (1.24–1.48)
Grouped midpoint age <50 1 1.69 (1.06–2.69) NS
50–59 10 1.14 (0.91–1.43)
60–69 2 1.35 (1.22–1.49)
a Based on blocks 1, 4, 6–10, 12, 14, 15, 17–19 as deﬁned in Table 1.
b The inverse-variance weighted mean of the log of the ratio, converted back to
the original scale.
c Probability values for testing for variation between levels of the factor con-
sidered, presented as <0.001, <0.01, <0.05, <0.1 or NS (pP 0.1). The probability level
is calculated based on the difference in deviance between the model with a com-
mon estimate of H and the model with a separate estimate of H ﬁtted for each level
of the factor studied.
d Blocks where risk was not separately estimated for males and females.
e Of principal publication for the study.
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marker level.
The third point relates to the difﬁculties in determining the
histological type of lung cancer type, where there is clear evidence
of variation between and within pathologists, within material from
the same patient, and by the source of specimen (e.g. Charloux
et al., 1997; Feinstein et al., 1970; Field et al., 2004; Lam, 1985;
Langer et al., 2010). It is also clear that changes in classiﬁcation
schemes over time by the WHO (Percy et al., 1990; Fritz et al.,
2000; Kreyberg, 1967; World Health Organization, 1976, 1982)
have had a substantial effect on the relative frequency of AdC to
SqC. For example, a study by Campobasso et al. (1993) compared
diagnoses by the same pathologists based on the WHO criteria
published in 1967 and 1982 (Kreyberg, 1967; World Health
Organization, 1982) and observed that the newer classiﬁcation
resulted in an increase in AdC by 94% and a reduction in SqC by
22%. The extent to which difﬁculties in diagnosis and differences
in classiﬁcation schemes may have affected our ﬁndings is difﬁcult
to assess, but it is clear that they have contributed to the observed
shift over time in the reported ratio of AdC to SqC. It should also be
noted that changes in diagnostic criteria over time should not have
materially affected our estimates of H by type. This is because the
estimates were carried out within study, with 14 of the 16 studies
of case-control design involving cases seen over a short period, and
both the cohort studies apparently using consistent criteria for
classiﬁcation over time.
Fourthly, changes in the distribution over time of current, for-
mer and never smokers may also have contributed to the observed
shift. While meta-analyses have shown that, in never smokers, the
estimated absolute risk of lung cancer is higher for AdC than for
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clearly much higher for SqC than for AdC (Lee et al., 2012a) so that
the estimated absolute risks of lung cancer tend to be higher for
SqC than for AdC for current smokers, but more similar for former
smokers (Lee and Forey, 2013). Generally, the lower the average
smoking dose received by a population, the higher the observed
ratio of AdC to SqC.
While it is beyond the scope of this paper to try to quantify
precisely the effect that changes in diagnosis and changes in the
distribution of smoking may have had on the observed ratio of
AdC to SqC in the US or any other population, it may be useful to
consider the extent to which greater H values for AdC than for
SqC may have increased the ratio of AdC to SqC in a population
which has substantially reduced smoking over a time. To gain some
insight into this, we considered a hypothetical population in which,
at baseline, 30% were never smokers, 20% were continuing smokers,
and 50% were current smokers just starting to quit. We assumed
never smoker rates of 10.5 and 21.2 per 100,000 per year for SqC
and AdC (Lee and Forey, 2013), as well as corresponding current
smoking RRs of 16.91 and 4.21 (Lee et al., 2012a), and H values of
11.68 and 14.45 (Table 7). At baseline, when 70% had current
smoker RRs, the ratio of AdC to SqC was 0.54. However, as time pro-
gressed, this increased steadily so that 50 years later it was 0.76, an
increase by a factor of 1.40. While this single hypothetical example
suggests that the moderately slower proportional decline in excess
risk following quitting for AdC than for SqC is not enough to explain
the larger observed shift in the ratio of AdC to SqC, it does indicate
that it makes some contribution. To assess the claims of the US
Surgeon General, 2014 more accurately would require a more com-
plex and multi-faceted analysis.
5. Conclusions
Our results show that it is possible to describe the observed
shape of the relationship between time quit and lung cancer quite
accurately using the relatively simple negative exponential model.
The estimated half life (H) is somewhat longer for AdC than for SqC
indicating that the ratio of the two lung cancer types increases
with increasing time quit. This ﬁnding may partly contribute to
the observed increase over time in the recorded ratio of AdC to SqC.
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